1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019.
Lancet Neurol 2021;20:795-820.
2. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association.
Stroke 2021;52:e364-e467.
3. Yaghi S, Elkind MSV. Cryptogenic stroke: a diagnostic challenge.
Neurol Clin Pract 2014;4:386-393.
4. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study.
Stroke 2001;32:2735-2740.
5. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
Stroke 1993;24:35-41.
6. Guercini F, Acciarresi M, Agnelli G, Paciaroni M. Cryptogenic stroke: time to determine aetiology.
J Thromb Haemost 2008;6:549-554.
7. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct.
Lancet Neurol 2014;13:429-438.
8. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source.
N Engl J Med 2018;378:2191-2201.
9. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source.
N Engl J Med 2019;380:1906-1917.
10. Geisler T, Keller T, Martus P, Poli K, Serna-Higuita LM, Schreieck J, et al. Apixaban versus aspirin for embolic stroke of undetermined source.
NEJM Evid 2024;3:EVIDoa2300235.
11. Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Marshall RS, Broderick JP, et al. Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial.
JAMA 2024;331:573-581.
12. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores.
Nat Rev Genet 2018;19:581-590.
13. Atchaneeyasakul K, Bates KE, Toledo A, Griswold AJ, Ramdas K, Watanabe M, et al. Utilizing RNA sequencing to identify gene expression markers of stroke-causing thrombi origin: a pilot study.
J Stroke Cerebrovasc Dis 2024;33:107518.
14. Roselli C, Surakka I, Olesen MS, Sveinbjornsson G, Marston NA, Choi SH, et al. Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases.
Nat Genet 2025;57:539-547.
15. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke.
N Engl J Med 2014;370:2467-2477.
16. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation.
N Engl J Med 2014;370:2478-2486.
17. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study.
Stroke 2013;44:3357-3364.
18. Mele F, Scopelliti G, La Volpe L, Ferrari Aggradi C, Molitierno N, Cova I, et al. Prediction scores of subclinical atrial fibrillation in patients with cryptogenic stroke and transient ischemic attack.
Int J Stroke 2025;20:1150-1158.
19. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25.
Nature 2007;448:353-357.
20. Tucker NR, Ellinor PT. Emerging directions in the genetics of atrial fibrillation.
Circ Res 2014;114:1469-1482.
22. All of Us Research Program Genomics Investigators. Genomic data in the All of Us Research Program.
Nature 2024;627:340-346.
23. Gajendragadkar PR, Von Ende A, Murgia F, Offer A, Camm CF, Wijesurendra RS, et al. Mechanistic pathways underlying genetic predisposition to atrial fibrillation are associated with different cardiac phenotypes and cardioembolic stroke risk.
Circ Genom Precis Med 2025;18:e004932.
24. Frerich S, Malik R, Georgakis MK, Sinner MF, Kittner SJ, Mitchell BD, et al. Cardiac risk factors for stroke: a comprehensive Mendelian randomization study.
Stroke 2022;53:e130-e135.
25. Georgakis MK, Parodi L, Frerich S, Mayerhofer E, Tsivgoulis G, Pirruccello JP, et al. Genetic architecture of stroke of undetermined source: overlap with known stroke etiologies and associations with modifiable risk factors.
Ann Neurol 2022;91:640-651.
26. Weng LC, Khurshid S, Gunn S, Trinquart L, Lunetta KL, Xu H, et al. Clinical and genetic atrial fibrillation risk and discrimination of cardioembolic from noncardioembolic stroke.
Stroke 2023;54:1777-1785.
27. Tack RWP, Tan BYQ, Senff JR, Prapiadou S, Kimball TN, Khurshid S, et al. Predicting atrial fibrillation after stroke by combining polygenic risk scores and clinical features.
Stroke 2025;56:878-886.
28. Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences.
J Am Coll Cardiol 2015;65:2239-2251.
29. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterisation, and clinical implication.
J Arrhythm 2016;32:247-278.
30. Habibi M, Zareian M, Ambale Venkatesh B, Samiei S, Imai M, Wu C, et al. Left atrial mechanical function and incident ischemic cerebrovascular events independent of AF: insights from the MESA study.
JACC Cardiovasc Imaging 2019;12:2417-2427.
31. Johansen MC, Doria de Vasconcellos H, Nazarian S, Lima JAC, Gottesman RF. The investigation of left atrial structure and stroke etiology: the I-LASER study.
J Am Heart Assoc 2021;10:e018766.
32. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE, et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial.
JAMA Neurol 2019;76:764-773.
33. Vad OB, Paludan-Müller C, Diederichsen SZ, McKaige EA, Monfort LM, Lundegaard PR, et al. Genetic determinants of left atrial function are associated with stroke.
J Am Heart Assoc 2024;13:e037490.
34. Yamaguchi N, Xiao J, Narke D, Shaheen D, Lin X, Offerman E, et al. Cardiac pressure overload decreases ETV1 expression in the left atrium, contributing to atrial electrical and structural remodeling.
Circulation 2021;143:805-820.
35. Ghazizadeh Z, Kiviniemi T, Olafsson S, Plotnick D, Beerens ME, Zhang K, et al. Metastable atrial state underlies the primary genetic substrate for MYL4 mutation-associated atrial fibrillation.
Circulation 2020;141:301-312.
36. Wang Y, Wang J, Shi L, Chen X, Li D, Cui C, et al. CIB2 Is a novel endogenous repressor of atrial remodeling.
Circulation 2023;147:1758-1776.
37. Collins MM, Ahlberg G, Hansen CV, Guenther S, Marín-Juez R, Sokol AM, et al. Early sarcomere and metabolic defects in a zebrafish pitx2c cardiac arrhythmia model.
Proc Natl Acad Sci U S A 2019;116:24115-24121.
38. Freilinger TM, Schindler A, Schmidt C, Grimm J, Cyran C, Schwarz F, et al. Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke.
JACC Cardiovasc Imaging 2012;5:397-405.
39. Ospel JM, Singh N, Marko M, Almekhlafi M, Dowlatshahi D, Puig J, et al. Prevalence of ipsilateral nonstenotic carotid plaques on computed tomography angiography in embolic stroke of undetermined source.
Stroke 2020;51:1743-1749.
40. Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, et al. Efficacy and safety of rivaroxaban versus aspirin in embolic stroke of undetermined source and carotid atherosclerosis.
Stroke 2019;50:2477-2485.
41. Rapillo CM, Giuricin A, Sarti C, Nesi M, Marcheselli S, Lombardo I, et al. Prevalence of carotid plaques with high-risk features in embolic stroke of undetermined source: systematic review and meta-analysis.
Int J Stroke 2025;20:636-645.
42. Kamtchum-Tatuene J, Wilman A, Saqqur M, Shuaib A, Jickling GC. Carotid plaque with high-risk features in embolic stroke of undetermined source: systematic review and meta-analysis.
Stroke 2020;51:311-314.
43. Song J, Jiang X, Cao Y, Juan J, Wu T, Hu Y. Interaction between an ATP-binding cassette A1 (ABCA1) variant and egg consumption for the risk of ischemic stroke and carotid atherosclerosis: a family-based study in the Chinese population.
J Atheroscler Thromb 2019;26:835-845.
44. Wang L, Yanuck D, Beecham A, Gardener H, Slifer S, Blanton SH, et al. A candidate gene study revealed sex-specific association between the OLR1 gene and carotid plaque.
Stroke 2011;42:588-592.
45. Alloza I, Salegi A, Mena J, Navarro RT, Martin C, Aspichueta P, et al. BIRC6 is associated with vulnerability of carotid atherosclerotic plaque.
Int J Mol Sci 2020;21:9387.
46. Yi XY, Liao DX, Wang C, Cheng W, Fu XQ, Zhang B. Cytochrome P450 genetic variants and their metabolite levels associated with plaque stability in patients with ischemic stroke.
J Atheroscler Thromb 2016;23:330-338.
48. Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, et al. Patent foramen ovale in young stroke patients.
Lancet 1988;2:11-12.
49. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, et al. Prevalence of patent foramen ovale in patients with stroke.
N Engl J Med 1988;318:1148-1152.
50. Mac Grory B, Ohman EM, Feng W, Xian Y, Yaghi S, Kamel H, et al. Advances in the management of cardioembolic stroke associated with patent foramen ovale.
BMJ 2022;376:e063161.
51. Cabanes L, Mas JL, Cohen A, Amarenco P, Cabanes PA, Oubary P, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography.
Stroke 1993;24:1865-1873.
52. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke.
Neurology 2013;81:619-625.
53. Kent DM, Saver JL, Kasner SE, Nelson J, Carroll JD, Chatellier G, et al. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke.
JAMA 2021;326:2277-2286.
54. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
N Engl J Med 2012;366:991-999.
55. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism.
N Engl J Med 2013;368:1083-1091.
56. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, Mac-Donald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
N Engl J Med 2013;368:1092-1100.
57. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke.
N Engl J Med 2017;377:1022-1032.
58. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke.
N Engl J Med 2017;377:1011-1021.
59. Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke.
N Engl J Med 2017;377:1033-1042.
60. Elliott DA, Kirk EP, Yeoh T, Chandar S, McKenzie F, Taylor P, et al. Cardiac homeobox gene NKX2-5 mutations and congenital heart disease: associations with atrial septal defect and hypoplastic left heart syndrome.
J Am Coll Cardiol 2003;41:2072-2076.
61. Kirk EP, Hyun C, Thomson PC, Lai D, Castro ML, Biben C, et al. Quantitative trait loci modifying cardiac atrial septal morphology and risk of patent foramen ovale in the mouse.
Circ Res 2006;98:651-658.
62. Morris JG, Singh S, Fisher M. Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good?
Stroke 2010;41:2985-2990.
63. Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG. Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale.
Stroke 2007;38:2070-2073.
64. Sgarra L, Bortone AS, Potenza MA, Nacci C, De Salvia MA, Acquaviva T, et al. Endothelial dysfunction may link interatrial septal abnormalities and MTHFR-inherited defects to cryptogenic stroke predisposition.
Biomolecules 2020;10:861.
65. Bersano A, Kraemer M, Burlina A, Mancuso M, Finsterer J, Sacco S, et al. Heritable and non-heritable uncommon causes of stroke.
J Neurol 2021;268:2780-2807.
66. Dichgans M. Genetics of ischaemic stroke.
Lancet Neurol 2007;6:149-161.
67. Mania-Pâris L, Vitobello A, Safraou H, Tran Mau-Them F, Duffourd Y, Nambot S, et al. Systematic genetic assessment in young patients with cryptogenic stroke: the ES-EASY project.
Stroke 2026;57:148-156.
68. Yaghi S, Bernstein RA, Passman R, Okin PM, Furie KL. Cryptogenic stroke: research and practice.
Circ Res 2017;120:527-540.
69. Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease.
Mol Genet Metab 2018;124:189-203.
70. Althubity AA. Homocystinuria: advances in metabolic and molecular therapies targeting homocysteine pathways (review).
Mol Med Rep 2026;33:34.
71. Soldatos A, Toro C, Hoffmann P, Romeo T, Deuitch N, Brofferio A, et al. TNF-blockade for primary stroke prevention in adenosine deaminase 2 deficiency: a case series.
Neurol Neuroimmunol Neuroinflamm 2023;10:e200073.
72. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes.
N Engl J Med 2014;371:2488-2498.
74. Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week.
J Am Coll Cardiol 2019;74:567-577.
75. Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, et al. Clonal hematopoiesis is associated with higher risk of stroke.
Stroke 2022;53:788-797.
76. Qiu X, Dai Y, Cheng S, Gu HQ, Jiang Y, Meng X, et al. Somatic mutation contributing to clonal haematopoiesis is a risk factor of recurrent stroke in first-ever acute ischaemic stroke: a prospective cohort study.
Stroke Vasc Neurol 2023;8:103-110.
77. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.
N Engl J Med 2017;377:111-121.
78. Ahn HJ, An HY, Ryu G, Lim J, Sun C, Song H, et al. Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.
Eur Heart J 2024;45:778-790.
79. Mayerhofer E, Strecker C, Becker H, Georgakis MK, Uddin MM, Hoffmann MM, et al. Prevalence and therapeutic implications of clonal hematopoiesis of indeterminate potential in young patients with stroke.
Stroke 2023;54:938-946.
80. Kim SG, Hong JM, Kim HY, Lee J, Chung PW, Park KY, et al. Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea.
Stroke 2010;41:798-801.
81. Rioux B, Touma L, Nehme A, Gore G, Keezer MR, Gioia LC. Frequency and predictors of occult cancer in ischemic stroke: a systematic review and meta-analysis.
Int J Stroke 2021;16:12-19.
82. Gon Y, Sakaguchi M, Takasugi J, Kawano T, Kanki H, Watanabe A, et al. Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occult cancer in patients with cryptogenic stroke.
Eur J Neurol 2017;24:503-508.
83. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons.
Blood 2019;133:781-789.
85. Navi BB, Mathias R, Sherman CP, Wolfe J, Kamel H, Tagawa ST, et al. Cancer-related ischemic stroke has a distinct blood mRNA expression profile.
Stroke 2019;50:3259-3264.
86. Lutgens E, Atzler D, Döring Y, Duchene J, Steffens S, Weber C. Immunotherapy for cardiovascular disease.
Eur Heart J 2019;40:3937-3946.
87. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease.
N Engl J Med 2017;377:1119-1131.
88. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation.
Nat Rev Cardiol 2015;12:230-243.
89. Shi K, Tian DC, Li ZG, Ducruet AF, Lawton MT, Shi FD. Global brain inflammation in stroke.
Lancet Neurol 2019;18:1058-1066.
90. Munshi A, Rajeshwar K, Kaul S, Al-Hazzani A, Alshatwi AA, Sai Babu M, et al. Interleukin-10-1082 promoter polymorphism and ischemic stroke risk in a South Indian population.
Cytokine 2010;52:221-224.
91. Munshi A, Rajeshwar K, Kaul S, Al-Hazzani A, Alshatwi AA, Shafi G, et al. Association of tumor necrosis factor-α and matrix metalloproteinase-3 gene variants with stroke.
Eur J Neurol 2011;18:1053-1059.
92. Georgakis MK, Gill D, Rannikmäe K, Traylor M, Anderson CD, Lee JM, et al. Genetically determined levels of circulating cytokines and risk of stroke.
Circulation 2019;139:256-268.
93. Jickling GC, Xu H, Stamova B, Ander BP, Zhan X, Tian Y, et al. Signatures of cardioembolic and large-vessel ischemic stroke.
Ann Neurol 2010;68:681-692.
94. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, et al. Stroke genetics informs drug discovery and risk prediction across ancestries.
Nature 2022;611:115-123.
95. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.
Nat Genet 2018;50:524-537.
97. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments.
Genome Med 2020;12:44.
98. Gibson JT, Rudd JHF. Polygenic risk scores in atrial fibrillation: associations and clinical utility in disease prediction.
Heart Rhythm 2024;21:913-918.
101. Truong B, Hull LE, Ruan Y, Huang QQ, Hornsby W, Martin H, et al. Integrative polygenic risk score improves the prediction accuracy of complex traits and diseases.
Cell Genom 2024;4:100523.
103. Li H, Zeng J, Snyder MP, Zhang S. Modeling gene interactions in polygenic prediction via geometric deep learning.
Genome Res 2025;35:178-187.
106. Cai X, Li H, Cao X, Ma X, Zhu W, Xu L, et al. Integrating transcriptomic and polygenic risk scores to enhance predictive accuracy for ischemic stroke subtypes.
Hum Genet 2025;144:43-54.
107. Labarga A, Martínez-Gonzalez J, Barajas M. Integrative multiomics analysis for etiology classification and biomarker discovery in stroke: advancing towards precision medicine.
Biology (Basel) 2024;13:338.
109. Yamamoto Y, Nagakane Y, Tanaka E, Yamada T, Fujinami J, Ohara T. How topographic diffusion-weighted imaging patterns can predict the potential embolic source.
Clin Neuroradiol 2024;34:363-371.
110. Yuan WZ, Shang L, Tian DS, Wu SW, You Y, Tian CL, et al. Monogenic basis of young-onset cryptogenic stroke: a multicenter study.
Ann Transl Med 2022;10:512.
111. Ilinca A, Martinez-Majander N, Samuelsson S, Piccinelli P, Truvé K, Cole J, et al. Whole-exome sequencing in 22 young ischemic stroke patients with familial clustering of stroke.
Stroke 2020;51:1056-1063.
113. Fitzgerald S, Dai D, Wang S, Douglas A, Kadirvel R, Layton KF, et al. Platelet-rich emboli in cerebral large vessel occlusion are associated with a large artery atherosclerosis source.
Stroke 2019;50:1907-1910.
114. Juega J, Palacio-Garcia C, Rodriguez M, Deck M, Rodriguez-Luna D, Requena M, et al. Monocyte-to-lymphocyte ratio in clot analysis as a marker of cardioembolic stroke etiology.
Transl Stroke Res 2022;13:949-958.
115. Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System.
Stroke 2007;38:2979-2984.
117. Tam V, Patel N, Turcotte M, Bossé Y, Paré G, Meyre D. Benefits and limitations of genome-wide association studies.
Nat Rev Genet 2019;20:467-484.
118. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 years of GWAS discovery: biology, function, and translation.
Am J Hum Genet 2017;101:5-22.
121. Lindgren AG, Braun RG, Juhl Majersik J, Clatworthy P, Mainali S, Derdeyn CP, et al. International stroke genetics consortium recommendations for studies of genetics of stroke outcome and recovery.
Int J Stroke 2022;17:260-268.
122. Majersik JJ, Cole JW, Golledge J, Rost NS, Chan YF, Gurol ME, et al. Recommendations from the international stroke genetics consortium, part 1: standardized phenotypic data collection.
Stroke 2015;46:279-284.
123. Rost NS, Meschia JF, Gottesman R, Wruck L, Helmer K, Greenberg SM; DISCOVERY Investigators. Cognitive impairment and dementia after stroke: design and rationale for the DISCOVERY study.
Stroke 2021;52:e499-e516.
125. Lee JY, Park JM, Lee J, Choi JC, Lee KJ, Sung J, et al. Building the future of precision medicine in stroke management: design and cohort profiles of the GENESIS-K study (abstract number: ESOC2026A1666). Eur Stroke J 2026;11(Suppl 1):i452.
126. Nederkoorn PJ, van Dijk EJ, Koudstaal PJ, Luijckx GJ, van Oostenbrugge RJ, Visser MC, et al. The Dutch String-of-Pearls Stroke Study: protocol of a large prospective multicenter genetic cohort study.
Int J Stroke 2015;10:120-122.
128. Cheng S, Xu Z, Liu Y, Lin J, Jiang Y, Wang Y, et al. Whole genome sequencing of 10K patients with acute ischaemic stroke or transient ischaemic attack: design, methods and baseline patient characteristics.
Stroke Vasc Neurol 2021;6:291-297.
129. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL.
Lancet Neurol 2009;8:643-653.
130. Yuan L, Chen X, Jankovic J, Deng H. CADASIL: a NOTCH3-associated cerebral small vessel disease.
J Adv Res 2024;66:223-235.
131. Tikka S, Baumann M, Siitonen M, Pasanen P, Pöyhönen M, Myllykangas L, et al. CADASIL and CARASIL.
Brain Pathol 2014;24:525-544.
132. Mancuso M, Arnold M, Bersano A, Burlina A, Chabriat H, Debette S, et al. Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology.
Eur J Neurol 2020;27:909-927.
133. Giau VV, Bagyinszky E, Youn YC, An SSA, Kim SY. Genetic factors of cerebral small vessel disease and their potential clinical outcome.
Int J Mol Sci 2019;20:4298.
134. Bang OY, Chung JW, Kim DH, Won HH, Yeon JY, Ki CS, et al. Moyamoya disease and spectrums of RNF213 vasculopathy.
Transl Stroke Res 2020;11:580-589.
136. Picod A, Joly BS, Veyradier A, Coppo P. Thrombotic thrombocytopenic purpura: a missed cause in stroke prevention guidelines.
Stroke 2025;56:1104-1105.
137. Kremer Hovinga JA, George JN. Hereditary thrombotic thrombocytopenic purpura.
N Engl J Med 2019;381:1653-1662.
138. Pfau K, Lengyel I, Ossewaarde-van Norel J, van Leeuwen R, Risseeuw S, Leftheriotis G, et al. Pseudoxanthoma elasticum - genetics, pathophysiology, and clinical presentation.
Prog Retin Eye Res 2024;102:101274.
139. Buso G, Corvini F, Fusco EM, Messina M, Cherubini F, Laera N, et al. Current evidence and future perspectives in the medical management of vascular Ehlers-Danlos syndrome: focus on vascular prevention.
J Clin Med 2024;13:4255.
142. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.
Circulation 2006;113:1807-1816.
143. Zaidi S, Brueckner M. Genetics and genomics of congenital heart disease.
Circ Res 2017;120:923-940.
144. Bouys L, Bertherat J. Management of endocrine disease: Carney complex: clinical and genetic update 20 years after the identification of the CNC1 (PRKAR1A) gene.
Eur J Endocrinol 2021;184:R99-R109.
145. Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1.
Neurology 2005;64:553-555.
146. Chen C, Chen P, Yu W, Zhao L, Yang Y, Qu H, et al. TGF-β-driven atrial fibrosis in atrial fibrillation: from mechanistic insights to targeted therapies. Aging Dis 2026;17:2509-2528.
147. D’Elia NW, Kistler PM, Voskoboinik A. Atrial fibrillation in the young: pathogenesis and clinical implications.
JACC Clin Electrophysiol 2025;11:1051-1066.
148. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited.
Lancet 2009;373:155-166.
149. Khan AA, Thomas GN, Lip GYH, Shantsila A. Endothelial function in patients with atrial fibrillation.
Ann Med 2020;52:1-11.
150. Larson AS, Brinjikji W, Lekah A, Klaas JP, Lanzino G, Huston J, et al. Nonstenotic carotid plaques and embolic stroke of undetermined source: a multimodality review.
AJNR Am J Neuroradiol 2023;44:118-124.
151. Kashiwazaki D, Koh M, Uchino H, Akioka N, Kuwayama N, Noguchi K, et al. Hypoxia accelerates intraplaque neovascularization derived from endothelial progenitor cells in carotid stenosis.
J Neurosurg 2018;131:884-891.
152. Goyal M, Singh N, Marko M, Hill MD, Menon BK, Demchuk A, et al. Embolic stroke of undetermined source and symptomatic nonstenotic carotid disease.
Stroke 2020;51:1321-1325.
153. Homma S, Messé SR, Rundek T, Sun YP, Franke J, Davidson K, et al. Patent foramen ovale.
Nat Rev Dis Primers 2016;2:15086.
154. Yan C, Li H, Wang C, Yu H, Guo T, Wan L, et al. Frequency and size of in situ thrombus within patent foramen ovale.
Stroke 2023;54:1205-1213.
156. Navi BB, Kasner SE, Cushman M, Okwuosa TM, Fleming NH, Behr JM, et al. Classification and management of ischemic stroke in patients with active cancer: a scientific statement from the American Heart Association.
Stroke 2026;57:e160-e173.
157. Ahmed O, King NE, Qureshi MA, Choudhry AA, Osama M, Zehner C, et al. Non-bacterial thrombotic endocarditis: a clinical and pathophysiological reappraisal.
Eur Heart J 2025;46:236-249.
158. Suomalainen OP, Martinez-Majander N, Broman J, Mannismäki L, Aro A, Curtze S, et al. Stroke in patients with atrial fibrillation: epidemiology, screening, and prognosis.
J Clin Med 2023;13:30.
159. Jordan K, Yaghi S, Poppas A, Chang AD, Mac Grory B, Cutting S, et al. Left atrial volume index is associated with cardioembolic stroke and atrial fibrillation detection after embolic stroke of undetermined source.
Stroke 2019;50:1997-2001.
160. Chousou PA, Chattopadhyay R, Ring L, Khadjooi K, Warburton EA, Mukherjee T, et al. Atrial fibrillation in embolic stroke of undetermined source: role of advanced imaging of left atrial function.
Eur J Prev Cardiol 2023;30:1965-1974.
161. Dhont S, Wouters F, Deferm S, Bekelaar K, Gruwez H, Meekers E, et al. Reduced left atrial appendage flow is associated with future atrial fibrillation after cryptogenic stroke.
J Am Soc Echocardiogr 2023;36:824-831.
162. Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model.
Stroke 2016;47:895-900.
163. Kühnlein P, Mahnkopf C, Majersik JJ, Wilson BD, Mitlacher M, Tirschwell D, et al. Atrial fibrosis in embolic stroke of undetermined source: a multicenter study.
Eur J Neurol 2021;28:3634-3639.
164. Clark A, Ferkh A, Vandenberg J, Elhindi J, Thomas L. Altered left atrial metrics in patients with cryptogenic stroke: a systematic review and meta-analysis.
Eur J Clin Invest 2024;54:e14175.
166. Kopczak A, Schindler A, Bayer-Karpinska A, Koch ML, Sepp D, Zeller J, et al. Complicated carotid artery plaques as a cause of cryptogenic stroke.
J Am Coll Cardiol 2020;76:2212-2222.
167. Coutinho JM, Derkatch S, Potvin AR, Tomlinson G, Kiehl TR, Silver FL, et al. Nonstenotic carotid plaque on CT angiography in patients with cryptogenic stroke.
Neurology 2016;87:665-672.
168. Luo N, Shang ZY, Tao L, Yang BQ, Chen HS. Atherosclerosis as a potential cause of deep embolic stroke of undetermined source: a 3T high-resolution magnetic resonance imaging study.
J Am Heart Assoc 2022;11:e026737.
169. Brunner G, Virani SS, Sun W, Liu L, Dodge RC, Nambi V, et al. Associations between carotid artery plaque burden, plaque characteristics, and cardiovascular events: the ARIC Carotid Magnetic Resonance Imaging Study.
JAMA Cardiol 2021;6:79-86.
170. Kent DM, Wang AY. Patent foramen ovale and stroke: a review.
JAMA 2025;334:1463-1473.
172. Pristipino C, Sievert H, D’Ascenzo F, Mas JL, Meier B, Scacciatella P, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism.
EuroIntervention 2019;14:1389-1402.
173. Kim BJ, Sohn H, Sun BJ, Song JK, Kang DW, Kim JS, et al. Imaging characteristics of ischemic strokes related to patent foramen ovale.
Stroke 2013;44:3350-3356.
175. Vidal-Calés P, Llull L, Lanthier S, Del Portillo JH, Desjardins L, Houde C, et al. Patent foramen ovale closure in older patients with cryptogenic stroke: current evidence and next steps.
Struct Heart 2025;9:100699.
176. Paolucci M, Vincenzi C, Romoli M, Amico G, Ceccherini I, Lattanzi S, et al. The genetic landscape of patent foramen ovale: a systematic review.
Genes (Basel) 2021;12:1953.
177. Nouh AM, Staff I, Finelli PF. Three territory sign: an MRI marker of malignancy-related ischemic stroke (Trousseau syndrome).
Neurol Clin Pract 2019;9:124-128.